{"id":"NCT00696384","sponsor":"Takeda","briefTitle":"A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension","officialTitle":"An 8-Month Phase 3, Open-Label Study With a Blinded Reversal Phase to Evaluate the Safety and Tolerability of TAK-491 in Subjects With Essential Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-06","primaryCompletion":"2009-04","completion":"2009-04","firstPosted":"2008-06-12","resultsPosted":"2012-01-04","lastUpdate":"2012-01-04"},"enrollment":418,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hypertension"],"interventions":[{"type":"DRUG","name":"Azilsartan medoxomil","otherNames":["TAK-491","Edarbi"]},{"type":"DRUG","name":"Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications.","otherNames":["TAK-491","Edarbi"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Azilsartan Medoxomil QD-Open Label Phase (Baseline - Week 26)","type":"EXPERIMENTAL"},{"label":"Azilsartan Medoxomil QD - Double-Blind Phase (Week 26-32)","type":"EXPERIMENTAL"},{"label":"Placebo QD - Double-Blind Phase (Week 26- 32)","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine the long term safety and tolerability of azilsartan medoxomil, once daily (QD), in participants with Essential Hypertension.","primaryOutcome":{"measure":"Change From Double-blind Baseline (Week 26) in Sitting Clinic Diastolic Blood Pressure to Week 32","timeFrame":"Double-blind Baseline (Week 26) and Week 32.","effectByArm":[{"arm":"Azilsartan Medoxomil QD - Double Blind Reversal Phase","deltaMin":0.14,"sd":0.726},{"arm":"Placebo QD - Double Blind Reversal Phase","deltaMin":7.92,"sd":0.712}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":45,"countries":["United States","Argentina","Mexico"]},"refs":{"pmids":["25619410"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":418},"commonTop":["Headache","Dizziness"]}}